Related Experiment Videos

Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder

Y Tanaka1, H Kawamata, K Fujimoto

  • 1Department of Pathology, Northwestern University Medical School, Chicago, Illinois 60611-3008, USA.

The Journal of Urology
|February 1, 1997
PubMed
Abstract

Insights

The anti-angiogenic factor TNP-470 effectively inhibits bladder tumor development by suppressing endothelial cell growth. Early-stage treatment with TNP-470 shows promise in preventing tumor recurrence and new growth.

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Angiogenesis plays a critical role in tumor growth and metastasis.
  • Anti-angiogenic therapies aim to inhibit the formation of new blood vessels that feed tumors.
  • TNP-470, a fumagillin analogue, exhibits anti-angiogenic properties.

Purpose of the Study:

  • To investigate the efficacy of TNP-470 in controlling bladder tumor development.
  • To evaluate the in vitro and in vivo effects of TNP-470 on tumor growth.

Main Methods:

  • In vitro assessment of TNP-470's effect on bovine capillary endothelial cell growth and migration.
  • In vivo study using a rat bladder cancer model, with TNP-470 instilled via urine after carcinogen exposure.
  • Tumor incidence was compared between TNP-470 treated and control groups.

Main Results:

  • TNP-470 selectively inhibited endothelial cell growth and migration in vitro.
  • Early instillation of TNP-470 significantly reduced bladder tumor incidence in rats (p < 0.05).
  • Control animals receiving only urine showed higher tumor incidence.

Conclusions:

  • TNP-470 demonstrates efficacy in suppressing bladder tumor development when initiated early.
  • The anti-angiogenic factor TNP-470 may serve as a preventative measure against bladder tumor recurrence and new tumor formation.

Related Concept Videos